GeneHealth - Your precision medicine

Premature Ovarian Failure

Disease Details

Family Health Simplified

Buy Membership

Description: Premature ovarian failure is a condition where the ovaries lose their normal function before the age of 40, leading to reduced estrogen production and infertility.
Type: Premature ovarian failure (POF), also known as primary ovarian insufficiency (POI), is often sporadic, but it can also be familial. The genetic transmission can be autosomal dominant, autosomal recessive, or X-linked, depending on the specific genetic mutation involved.
Signs And Symptoms: The signs and symptoms of POI can be seen as part of a continuum of changes leading to menopause. POI contrasts with age-appropriate menopause in the age of onset, degree of symptoms and sporadic return to normal ovarian function. As some women retain partial ovarian function, symptoms may not be as severe as regular menopause. In others, particularly with coexistent depression, symptoms such as decreased quality of life can be severe.Hormonally, POI is defined by abnormally low levels of estrogen and high levels of FSH, which demonstrate that the ovaries are no longer responding to circulating FSH by producing estrogen and developing fertile eggs. The ovaries will likely appear smaller than normal. The age of onset can be as early as 11 years. POI can be seen as part of a continuum of changes leading to menopause that differ from age-appropriate menopause in the age of onset, degree of symptoms, and sporadic return to normal ovarian function. A contrasting problem can be when a girl never begins menstruation due to a genetic condition causing primary amenorrhea.
Prognosis: Primary ovarian insufficiency is associated with co-morbidities associated with menopause including osteoporosis (decreased bone density), which affects almost all women with POI due to an insufficiency of estrogen. There is also an increased risk of heart disease, hypothyroidism such as Hashimoto's thyroiditis, Addison's disease, and other autoimmune disorders.
Onset: Premature ovarian failure (POF) typically has an onset before the age of 40. It is characterized by the cessation of ovarian function, leading to decreased estrogen levels and infertility. Symptoms may include irregular or absent menstrual periods, hot flashes, night sweats, vaginal dryness, irritability, and difficulty concentrating.
Prevalence: Premature ovarian failure, also known as primary ovarian insufficiency, affects approximately 1% of women under the age of 40. It is characterized by the loss of normal ovarian function before the age of 40, leading to reduced estrogen production and infertility.
Epidemiology: The prevalence increases with age and is approximately 1 in 10,000 women under age 20, 1 in 1,000 women under age 30, and one percent by age of 40. It occurs in 3.7% of women worldwide and 1% of women in the United States. In the United States, the incidence is 1% in White women, 1.4% in Black and Hispanic women, with lower rates seen in Chinese and Japanese women, at 0.5% and 0.1% respectively.
Intractability: Premature ovarian failure (POF), also known as primary ovarian insufficiency, is often considered intractable in terms of completely reversing the condition. While the restoration of normal ovarian function is rare, management approaches like hormone replacement therapy can help alleviate symptoms and address associated health risks. Fertility treatment options, such as in vitro fertilization with donor eggs, may also be considered for those seeking to conceive. However, there is currently no cure that restores normal ovarian function permanently.
Disease Severity: Premature ovarian failure (POF), also known as primary ovarian insufficiency, is a condition characterized by the loss of normal ovarian function before the age of 40. The severity of POF can vary among individuals, but it generally results in reduced fertility or infertility, as well as symptoms associated with estrogen deficiency, such as irregular or absent menstrual periods, hot flashes, and vaginal dryness. The long-term consequences may include increased risks of osteoporosis and cardiovascular disease due to the lack of estrogen.
Healthcare Professionals: Disease Ontology ID - DOID:5426
Pathophysiology: Pathophysiology:

Premature ovarian failure (POF), also known as primary ovarian insufficiency (POI), involves the loss of normal ovarian function before the age of 40. This condition is characterized by decreased or absent ovarian follicles and impaired estrogen production, leading to irregular or absent menstrual cycles (amenorrhea) and infertility. The exact pathophysiology of POF can vary and may involve genetic factors, autoimmune responses, or environmental influences such as chemotherapy or radiation. Genetic mutations associated with POF can affect genes involved in ovarian function and folliculogenesis. Autoimmune causes involve the body producing antibodies that attack ovarian tissue. The result is follicle depletion or dysfunction leading to reduced production of sex hormones, primarily estrogen, and increased levels of gonadotropins (FSH and LH) due to the lack of negative feedback from the ovaries.
Carrier Status: Premature ovarian failure (POF), also known as primary ovarian insufficiency, is typically not associated with a single gene mutation that can be carried in a simple Mendelian inheritance pattern. While genetic factors can contribute to POF, it is often influenced by a combination of genetic, autoimmune, and environmental factors. Because there isn't a specific gene mutation universally linked to POF that would define a clear carrier status, it is generally not referred to in terms of carrier status.
Mechanism: The pathogenic mechanisms of POI are highly heterogeneous and can be divided into four major categories: follicular migration defect early in embryogenesis; an early decrease in the primordial follicles; increased follicular death; and altered maturation or recruitment of primordial follicles. These result in a decrease of the ovaries' general supply of eggs that normally lasts until an average age of 51 for age of age-appropriate menopause.Genetic causes such as Turner syndrome have initial ovarian development but then ovaries degenerate rapidly during prenatal life, often leading to gonadal dysgenesis with streak ovaries. In those cases where POI is associated with adrenal autoimmunity, histological examination almost always confirms the presence of an autoimmune oophoritis in which follicles are infiltrated by lymphocytes, plasma cells, and macrophages that attack mainly steroid-producing cells and eventually result in follicular depletion.In some women FSH may bind to the FSH receptor site, but be inactive. By lowering the endogenous FSH levels with ethinylestradiol (EE) or with a GnRH-a the receptor sites are free and treatment with exogenous recombinant FSH activates the receptors and normal follicle growth and ovulation can occur. (Since the serum Anti-Müllerian hormone (AMH) level is correlated with the number of remaining primordial follicles some researchers believe the above two phenotypes can be distinguished by measuring serum AMH levels.Genetic associations include genetic disorders, autoimmune diseases, enzyme defects, and resistant ovaries.Mutations in FOXL2 cause blepharophimosis, ptosis, epicanthus inversus syndrome (BPES). Premature ovarian failure is part of the BPES Type I variant of the syndrome but not of the BPES Type II variant.
Treatment: Premature ovarian failure (POF), also known as primary ovarian insufficiency (POI), is a condition characterized by the loss of normal ovarian function before the age of 40.

Treatment options for POF include:

1. **Hormone Replacement Therapy (HRT):** To provide estrogen and progesterone, reduce menopausal symptoms, and protect against osteoporosis.
2. **Calcium and Vitamin D Supplements:** To maintain bone health and prevent osteoporosis.
3. **Fertility Treatment:** Options such as in vitro fertilization (IVF) with donor eggs for those desiring pregnancy.
4. **Lifestyle Modifications:** Including regular exercise, a balanced diet, and cessation of smoking to support overall health.
5. **Psychological Support:** Counseling or support groups to address emotional and psychological aspects of the condition.

A tailored treatment plan should be developed in consultation with a healthcare provider.
Compassionate Use Treatment: Premature ovarian failure (POF), also known as primary ovarian insufficiency (POI), is a condition where the ovaries stop functioning properly before the age of 40. There are several avenues of treatment under compassionate use or considered off-label/experimental:

1. **Hormone Replacement Therapy (HRT):**
- While not experimental, HRT is commonly used off-label to manage symptoms and reduce long-term health risks associated with POF, such as osteoporosis and cardiovascular disease.

2. **Dehydroepiandrosterone (DHEA) Supplements:**
- DHEA is sometimes used off-label to improve ovarian function and increase fertility chances, though more research is needed to confirm its efficacy.

3. **Autoimmune Treatment:**
- For cases suspected to be related to autoimmune processes, treatments such as corticosteroids or other immunomodulating drugs may be used off-label.

4. **Stem Cell Therapy:**
- Experimental treatments using stem cells aim to regenerate ovarian function. This therapy is still under clinical investigation and not widely available.

5. **Platelet-Rich Plasma (PRP) Injections:**
- PRP therapy is experimental and involves injecting concentrated platelets into the ovaries to stimulate tissue regeneration and follicle growth.

6. **Alternative and Complementary Therapies:**
- Some women explore acupuncture, herbal supplements, or other alternative treatments, though these lack robust scientific validation.

Use of these treatments should be under the guidance of a healthcare provider, particularly those that are experimental or off-label, to ensure safety and appropriateness for the individual's specific health situation.
Lifestyle Recommendations: Lifestyle recommendations for managing premature ovarian failure, also known as primary ovarian insufficiency, typically include:

1. **Balanced Diet**: Consuming a diet rich in fruits, vegetables, whole grains, and lean proteins can help maintain overall health.
2. **Regular Exercise**: Engaging in regular physical activity can improve mood, bone health, and cardiovascular health.
3. **Calcium and Vitamin D**: Ensuring adequate intake of calcium and vitamin D to support bone health and reduce the risk of osteoporosis.
4. **Avoid Smoking**: Smoking can exacerbate symptoms and affect overall health negatively.
5. **Limit Alcohol**: Reducing alcohol intake can help manage symptoms and improve overall health.
6. **Stress Management**: Practicing stress-reducing activities such as yoga, meditation, or deep-breathing exercises can improve mental well-being.
7. **Regular Medical Check-Ups**: Frequent visits to a healthcare provider to monitor health conditions associated with premature ovarian failure, such as cardiovascular health and bone density.

These recommendations can help manage symptoms and improve quality of life for those with premature ovarian failure.
Medication: Premature ovarian failure (POF), also known as primary ovarian insufficiency (POI), is the loss of normal ovarian function before the age of 40. Treatments primarily aim to manage symptoms and reduce long-term health risks. Common medications used for POF include hormone replacement therapy (HRT) to replace estrogen and progesterone, and possibly fertility treatments if pregnancy is desired. Additionally, calcium and vitamin D supplements may be recommended to support bone health. It's essential for patients to consult healthcare providers for personalized treatment plans.
Repurposable Drugs: Repurposable drugs for premature ovarian failure (POF) include:

1. **Hormone Replacement Therapy (HRT)**: Commonly used to manage symptoms and maintain bone density.
2. **Dehydroepiandrosterone (DHEA)**: Some studies explore its use for improving ovarian function.
3. **Metformin**: Often used for insulin resistance, it has been examined for its potential impact on ovarian function.

These drugs are being researched for their therapeutic benefits in managing or potentially reversing POF symptoms.
Metabolites: Premature ovarian failure (POF), also known as primary ovarian insufficiency, involves the early loss of normal ovarian function before age 40. Studies have indicated that certain metabolites are altered in POF, such as decreased levels of estradiol and increased levels of follicle-stimulating hormone (FSH). Additionally, lipid metabolism and amino acid pathways may be disrupted.
Nutraceuticals: Currently, there is limited evidence supporting the use of nutraceuticals for the treatment of premature ovarian failure (POF). Nutraceuticals refer to food-derived products that purport to offer health benefits, beyond basic nutrition, including the use of dietary supplements.

However, some commonly discussed nutraceuticals in relation to ovarian health include antioxidants such as vitamins C and E, coenzyme Q10, omega-3 fatty acids, and certain phytoestrogens like those found in soy products. These compounds are believed to reduce oxidative stress and may support hormonal balance. Despite this, their efficacy specifically for POF has not been conclusively demonstrated in clinical research.

It's essential to consult a healthcare provider before starting any new treatment regimen, including nutraceuticals, especially for a condition as complex as premature ovarian failure.
Peptides: Premature ovarian failure (POF), also known as primary ovarian insufficiency, is a condition where the ovaries lose their normal function before the age of 40. Peptides that have been investigated in research related to POF include follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which are crucial for ovarian function. However, specific therapeutic peptides for POF are still under investigation. The term "nan" likely refers to nanoparticles, which are being explored for targeted drug delivery in various medical conditions, including ovarian insufficiency. Nanoparticles may offer a promising approach to deliver therapeutic agents directly to the ovaries, potentially improving treatment efficacy for POF.